Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05153135 · ClinicalTrials.gov registry record
Description of Treatment Patterns and Description and Comparison of Healthcare Resource Utilization and Costs of Women With Metastatic HR+/HER2- Breast Cancer Treated With CDK4/6 Inhibitors
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 4,320
- Enrollment target
NCT05153135 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 4,320 participants.
The verdict
NCT05153135 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 4,320 participants
- Enrollment target
Study Summary
The study was an observational, retrospective cohort design, using US administrative insurance claims data, to better understand Healthcare resource utilization (HRU) and healthcare costs among women with mBC initiated on a CDK4/6 inhibitor.
Interventions
- DRUG Palbociclib
- DRUG Abemaciclib
- DRUG Ribociclib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,320 participants |
| Start Date | 2020-05-08 |
| Est. Completion | 2020-07-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05153135
The ClinicalTrials.gov registry entry for NCT05153135 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 4,320 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Palbociclib is the first listed.
NCT05153135 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05153135 about?
NCT05153135 is a clinical study titled "Description of Treatment Patterns and Description and Comparison of Healthcare Resource Utilization and Costs of Women With Metastatic HR+/HER2- Breast Cancer Treated With CDK4/6 Inhibitors". The study was an observational, retrospective cohort design, using US administrative insurance claims data, to better understand Healthcare resource utilization (HRU) and healthcare costs among women with mBC initiated on a CDK4/6 inhibitor.
What is the current status of trial NCT05153135?
This trial is currently completed. The enrollment target is 4,320 participants. The study started on 2020-05-08. Estimated completion is 2020-07-31.
What interventions are being tested in trial NCT05153135?
The interventions under investigation include: Palbociclib (DRUG), Abemaciclib (DRUG), Ribociclib (DRUG).
Who is sponsoring clinical trial NCT05153135?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.